Compounded Semaglutide & Tirzepatide in 2026: FDA Rules, Safety Risks, and How to Choose a Legitimate Pharmacy Joshua Silva, MD Oct 3, 2025 5 min read Updated: Jan 21 Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD As of 2026, compounded semaglutide and tirzepatide are no longer broadly permitted in the United States
Optimal benefits, especially in terms of skin tone and overall vitality, are typically seen with regular injections over several months
Cesarean delivery rates were higher among women using a GLP-1 1 year prior to delivery ( P = .007) and 2 years before delivery ( P = .033) vs
1 GLP-1RAs improve blood glucose control and aid in weight loss by promoting insulin release, inhibiting glucagon secretion, slowing gastric emptying, and promoting neurohormonal satiety
The evidence is unambiguous